Equities researchers at Northland Securities assumed coverage on shares of Viveve Medical (NASDAQ:VIVE) in a research report issued to clients and investors on Friday. The brokerage set an “outperform” rating and a $8.00 price target on the stock. Northland Securities’ price objective would indicate a potential upside of 60.97% from the company’s current price.
A number of other equities analysts have also weighed in on the stock. ValuEngine lowered shares of Viveve Medical from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Mizuho started coverage on shares of Viveve Medical in a research report on Thursday, November 16th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Cowen set a $11.00 price objective on shares of Viveve Medical and gave the company a “buy” rating in a research report on Monday, October 23rd. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $10.00.
Viveve Medical (NASDAQ VIVE) traded down $0.22 during trading hours on Friday, hitting $4.97. 250,000 shares of the stock were exchanged, compared to its average volume of 138,267. The company has a current ratio of 3.89, a quick ratio of 3.63 and a debt-to-equity ratio of 2.72. The firm has a market capitalization of $96.55, a price-to-earnings ratio of -2.31 and a beta of -0.67. Viveve Medical has a twelve month low of $3.75 and a twelve month high of $11.16.
A number of hedge funds have recently modified their holdings of VIVE. Rhumbline Advisers acquired a new position in Viveve Medical during the second quarter worth approximately $110,000. JPMorgan Chase & Co. acquired a new position in Viveve Medical during the second quarter worth approximately $151,000. Virtu KCG Holdings LLC acquired a new position in Viveve Medical during the second quarter worth approximately $169,000. Schwab Charles Investment Management Inc. acquired a new position in Viveve Medical during the second quarter worth approximately $189,000. Finally, California State Teachers Retirement System acquired a new position in Viveve Medical during the second quarter worth approximately $190,000. 66.90% of the stock is owned by hedge funds and other institutional investors.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.